• Submit to Pharmaceuticals Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [241 KB]

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Ferraldeschi, R
• Newman, W
• [+] on Google Scholar
• Ferraldeschi, R
• Newman, W
• [+] on PubMed
• Ferraldeschi, R
• Newman, W

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Pharmaceuticals 2010, 3(4), 1122-1138; doi:10.3390/ph3041122

Review

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Roberta Ferraldeschi ^1,2  and William G. Newman ^2,*

¹ Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK ² Genetic Medicine, St Mary\'s Hospital, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Oxford Road, Manchester, M13 9WL, UK

* Author to whom correspondence should be addressed.

Received: 30 December 2009; in revised form: 12 March 2010 / Accepted: 9 April 2010 / Published: 15 April 2010

(This article belongs to the Special Issue Personalized Medicine)

Download PDF Full-Text [241 KB, uploaded 15 April 2010 09:11 CEST]

Abstract: Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.

Keywords: tamoxifen; CYP2D6 genotyping; breast cancer

Article Statistics

Cite This Article